NCAPG is a prognostic biomarker of immune infiltration in non-small-cell lung cancer
Abstract
Purpose: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths. The protein NCAPG plays a significant role in tumor development. Patients & methods: We set up a tissue microarray (containing 140 NSCLC and ten normal lung tissues) and performed immunohistochemistry to assess NCAPG expression in the tissues of 140 patients. The prognostic value of NCAPG in NSCLC was assessed using the univariate and multivariate Cox proportional hazards regression models and Kaplan–Meier plots. We analyzed the association between NCAPG and immune infiltration in NSCLC. Results: Multifactorial analysis and Kaplan–Meier plots revealed that upregulation of NCAPG expression was an independent factor in the prognosis of NSCLC. Data from CIBERSORT showed a negative correlation between NCAPG and the expression of memory CD4+ T cells, CD8+ T cells, dendritic cells, macrophages, mast cells and natural killer cells (p < 0.001). Gene set enrichment analysis revealed that cell cycle, adhesion and proliferation were significantly enriched in samples with a high NCAPG expression. Conclusion:NCAPG is a novel biomarker of prognosis and is associated with immune cell infiltration in the tumor microenvironment. Thus it may be a potential target in NSCLC treatment.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Cancer statistics, 2017. CA Cancer J. Clin. 67(1), 7–30 (2017). • Indicates that non-small cell lung cancer (NSCLC) has the highest number of lung cancer-related deaths of all cancers in men and women worldwide.
- 2. . Epidemiology of lung cancer in China. Thorac. Cancer 10(1), 3–7 (2019).
- 3. . SnapShot: TCGA-analyzed tumors. Cell 173(2), 530 (2018).
- 4. Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC. Cancer Med. 7(5), 1988–2002 (2018).
- 5. . NCAPG upregulation mediated by four microRNAs combined with activation of the p53 signaling pathway is a predictor of poor prognosis in patients with breast cancer. Oncol. Lett. 21(4), 323 (2021). •• NCAPG upregulation is a predictor of poor prognosis in NSCLC patients.
- 6. NCAPG promotes the proliferation of hepatocellular carcinoma through PI3K/Akt signaling. Onco Targets Ther. 12, 8537–8552 (2019).
- 7. NCAPG Is a promising therapeutic target across different tumor types. Front Pharmacol. 11, 387 (2020).
- 8. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer. Cell Death Dis. 11(7), 547 (2020).
- 9. . The interplay between microRNAs and cellular components of tumour microenvironment (TME) on non-small-cell lung cancer (NSCLC) progression. J. Immunol. Res. 2019, 3046379 (2019).
- 10. Long non-coding RNA RFPL3S is a novel prognostic biomarker in lung cancer. Oncol Lett. 20(2), 1270–1280 (2020).
- 11. . COL1A1 is a prognostic biomarker and correlated with immune infiltrates in lung cancer. PeerJ 9, e11145 (2021).
- 12. . NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 25(23), 7238–7251 (2021).
- 13. Aberrant expression of NCAPG is associated with prognosis and progression of gastric cancer. Cancer Manag. Res. 12, 7837–7846 (2020). •• Aberrant expression of NCAPG is associated with the prognosis and progression of many cancers.
- 14. . Dysregulation of NCAPG, KNL1, miR-148a-3p, miR-193b-3p, and miR-1179 may contribute to the progression of gastric cancer. Biol. Res. 51(1), 44 (2018).
- 15. NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway. Cancer Cell Int. 21(1), 443 (2021). •• NCAPG is a multifunctional peptide involved in cell proliferation, migration, apoptosis, tumorigenesis and innate immune response.
- 16. . Inhibition of NCAPG expression inactivates the Wnt/β-catenin signal to suppresses endometrial cancer cell growth in vitro. Environ. Toxicol. 36(12), 2512–2520 (2021).
- 17. LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers. Front. Immunol. 10, 6 (2019).
- 18. Prognostic biomarker MITD1 and its correlation with immune infiltrates in hepatocellular carcinoma (HCC). Int. Immunopharmacol. 81, 106222 (2020).
- 19. BICC1 as a novel prognostic biomarker in gastric cancer correlating with immune infiltrates. Int. Immunopharmacol. 87, 106828 (2020).
- 20. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer. J. Cell. Mol. Med. 24(15), 8674–8686 (2020).
- 21. NCAPG induces cell proliferation in cardia adenocarcinoma via PI3K/AKT signaling pathway. Onco Targets Ther. 13, 11315–11326 (2020).
- 22. TGFβ2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer. J. Cell. Mol. Med. 24(13), 7151–7162 (2020).
- 23. Overexpression of NCAPG inhibits cardia adenocarcinoma apoptosis and promotes epithelial–mesenchymal transition through the Wnt/β-catenin signaling pathway. Gene 766, 145163 (2021). •• These findings suggested a potential association between NCAPG expression and levels of immune infiltration in NSCLC.
- 24. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978–985 (2018).
- 25. Immune infiltration in invasive lobular breast cancer. J. Natl Cancer Inst. 110(7), 768–776 (2018).
- 26. . Non-SMC condensin I complex, subunit G (NCAPG) is a novel mitotic gene required for hepatocellular cancer cell proliferation and migration. Oncol. Res. 26(2), 269–276 (2018).
- 27. GSEA of mouse and human mitochondriomes reveals fatty acid oxidation in astrocytes. Glia 66(8), 1724–1735 (2018).